Samedan Ltd Pharmaceutical Publishers


Advanced search

Publications European Pharmaceutical Contractor European Biopharmaceutical Review International Clinical Trials Pharmaceutical Manufacturing and Packing Sourcer Innovations in Pharmaceutical Technology Subscribe Online Conferences White Papers Samedan app Pharmaceutical Directory Industry Events Calendar News and Press Releases Employment Opportunities Advertising with us Contact Us

home >

PUBLICATIONS

	Subscribe
	Current Issue
	Archives
	Media Info
	Our Clients

Featured in this issue

Paving the Way

Rik Van Mol at Veeva Systems

In order to drive efficiency and a faster time to market, sponsors, CROs, and pharma companies need to embrace collaboration.

The Elephant in the Room

Kurt Mussina at Frenova Renal Research

Systematic and concrete marketing activities are an often overlooked aspect of a successful clinical research business.

A Scalable Solution

Susan Najjar at Covance

It is important for smaller enterprises to seek specialised clinical and regulatory support in order to streamline pre- and post-marketing phases.

News and Press Releases

Global Clinical Trial Supplies Specialist RxSource invests in clinical labelling software to enhance service offering

PRISYM ID, a leading provider of regulated content and label management solutions, announced today that Global Clinical Trial Supplies Specialist RxSource has invested in the innovative PRISYM 360 clinical labelling platform. The software will enable RxSource to optimize its demand-led secondary packaging and labelling services, and supply medicines faster.
More info >>

All releases >>

White Papers

Pandemic respiratory vaccine clinical trials: a departure from business as usual

ICON plc

Around the world, the “V” words are on everyone’s lips: Virus and Vaccines. In response to the urgent need for a vaccine for COVID-19, researchers are, at time of publication, running 500+ clinical trials (and counting) on a number of antivirals, antibodies and vaccines. Promising possibilities range from novel new drugs/vaccines, repurposing treatments currently indicated for HIV, Ebola and malaria, to monoclonal antibodies and immune serum.
More info >>

All white papers >>